<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02347904</url>
  </required_header>
  <id_info>
    <org_study_id>NL49889.018.14</org_study_id>
    <nct_id>NCT02347904</nct_id>
  </id_info>
  <brief_title>Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer</brief_title>
  <acronym>SOX</acronym>
  <official_title>Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective single arm study the investigators will assess the feasibility of S-1 and&#xD;
      Oxaliplatin as adjuvant treatment in patients with esophageal cancer.&#xD;
&#xD;
      The primary objective is to assess the feasibility of administering adjuvant S-1 and&#xD;
      Oxaliplatin (SOX) in patients with esophageal cancer after neoadjuvant chemoradiotherapy with&#xD;
      paclitaxel and carboplatin and esophagectomy. Primary end point is the percentage of patients&#xD;
      completing the preplanned number of 6 cycles of SOX.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since the outcome of patients with esophageal cancer treated with neoadjuvant chemoradiation&#xD;
      and surgery is still poor, strategies to improve survival should be explored. The benefit of&#xD;
      adjuvant chemotherapy after neoadjuvant chemoradiotherapy followed by surgery is unknown.&#xD;
      Preferably, such adjuvant chemotherapy regimen should consist of a non-cross resistant,&#xD;
      well-tolerated schedule. For this purpose, the combination of S-1, an oral fluoropyrimidine,&#xD;
      with oxaliplatin, may be of benefit, as each of these compounds have shown efficacy in&#xD;
      gastroesophageal cancer. Also, importantly, the combination of S-1 with oxaliplatin (SOX) in&#xD;
      advanced gastric cancer was well-tolerated. Nevertheless, it should be acknowledged that&#xD;
      after major surgery for esophageal cancer, adjuvant treatment with combination chemotherapy&#xD;
      may be hard to accomplish as was shown in the MAGIC trial for gastric cancer where less than&#xD;
      half of all patients completed adjuvant therapy.&#xD;
&#xD;
      Therefore the investigators want to assess the feasibility of an adjuvant treatment scheme&#xD;
      with S-1 and Oxaliplatin. When the proposed treatment scheme is feasible the potential&#xD;
      benefit on survival will be evaluated in further studies. Feasibility is defined ≥50% of&#xD;
      patients completing the pre-planned number of cycles&#xD;
&#xD;
      Study Objectives Primary Objective To assess the feasibility of administering adjuvant SOX in&#xD;
      patients with esophageal cancer after neoadjuvant chemoradiotherapy with paclitaxel and&#xD;
      carboplatin and esophagectomy&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
        1. Percentage of patients completing 6 cycles of S-1 (with or without oxaliplatin).&#xD;
&#xD;
        2. Dose modifications (ie, delays, dose reductions, or interruptions) for S-1.&#xD;
&#xD;
        3. Dose modifications (ie, delays, dose reductions, or interruptions) for oxaliplatin.&#xD;
&#xD;
        4. Dose intensity of S-1.&#xD;
&#xD;
        5. Dose intensity of oxaliplatin.&#xD;
&#xD;
        6. Toxicity.&#xD;
&#xD;
        7. Disease free survival.&#xD;
&#xD;
      Exploratory Objectives&#xD;
&#xD;
        1. Assessment of pharmacokinetics of S1 as predictive factors for efficacy and toxicity.&#xD;
&#xD;
        2. Potential biomarker development based on assessment of archived tumor tissue and blood&#xD;
           samples and the proposed mechanism of action of study drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">November 2019</completion_date>
  <primary_completion_date type="Actual">November 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients completing the preplanned number of 6 cycles of SOX.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients completing 6 cycles of S-1 (with or without oxaliplatin)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose modifications for S-1</measure>
    <time_frame>24 months</time_frame>
    <description>in terms of delay of treatment in weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose modifications for S-1</measure>
    <time_frame>24 months</time_frame>
    <description>in terms of dose reduction in percentage of orginal dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose modifications for S-1</measure>
    <time_frame>24 months</time_frame>
    <description>in terms of number of interruptions of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose modifications for Oxaliplatin</measure>
    <time_frame>24 months</time_frame>
    <description>in terms of delay of treatment in weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose modifications for Oxaliplatin</measure>
    <time_frame>24 months</time_frame>
    <description>in terms of dose reduction in percentage of orginal dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose modifications for Oxaliplatin</measure>
    <time_frame>24 months</time_frame>
    <description>in terms of number of interruptions of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose intensity for S-1</measure>
    <time_frame>24 months</time_frame>
    <description>total received dose of S-1 in mg/m2 per week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose intensity for Oxaliplatin</measure>
    <time_frame>24 months</time_frame>
    <description>total received dose of oxaliplatin in mg/m2 per week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>24 months</time_frame>
    <description>in terms of CTCAE v4.0 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>24 months</time_frame>
    <description>in months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>in months</description>
  </secondary_outcome>
  <other_outcome>
    <measure>AUC of S-1</measure>
    <time_frame>24 months</time_frame>
    <description>assessment of pharmacokinetics (Cmax/T1/2) in relation to toxicity in terms of CTCAE criteria and efficacy in terms of disease free survival</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Adjuvant S-1 and Oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvant treatment with s-1 and oxaliplatin after neoadjuvant chemoradiation and esophagectomy in patients with resectable esophageal cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1 and Oxaliplatin</intervention_name>
    <description>Six courses of oxaliplatin (130 mg/m2) intravenously on day 1 and S-1 (25 mg/m2 b.i.d.) orally from day 1 to 14 every 3 weeks, starting within 12 weeks after esophagectomy</description>
    <arm_group_label>Adjuvant S-1 and Oxaliplatin</arm_group_label>
    <other_name>Teysuno</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Radically resected adenocarcinoma of the esophagus&#xD;
&#xD;
          -  Completed neoadjuvant treatment with paclitaxel 50 mg/m2 and carboplatin Area Under&#xD;
             Curve (AUC) = 2 on days 1, 8, 15, 22 and 29 and radiotherapy to a total dose of 41.4&#xD;
             Gy in 23 fractions of 1.8 Gy, 5 fractions per week.&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  Adequate bone marrow function (Hb ≥ 6.0 mmol/L, absolute neutrophil count ≥1.0 x&#xD;
             109/L, - platelets ≥ 100 x 109/L), renal function (serum creatinine ≤ 1.5x ULN and&#xD;
             creatinine clearance, Cockroft formula, ≥30 ml/min), liver function (serum bilirubin ≤&#xD;
             2 x Upper Limit Normal (ULN), serum transaminases ≤ 3 x).&#xD;
&#xD;
          -  Negative pregnancy test in women with childbearing potential.&#xD;
&#xD;
          -  Expected adequacy of follow-up.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history or clinical signs of metastasis&#xD;
&#xD;
          -  History of a second malignancy &lt;5 years with the exception of adequately treated&#xD;
             carcinoma of cervix or basal/squamous cell carcinoma of skin.&#xD;
&#xD;
          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency or treatment within 4 weeks&#xD;
             with DPD inhibitors, including sorivudine or its chemically related analogues such as&#xD;
             brivudine.&#xD;
&#xD;
          -  Significant cardiovascular disease &lt; 1 yr before start of the study (symptomatic&#xD;
             congestive heart failure, myocardial ischemia or infarction, unstable angina pectoris,&#xD;
             serious uncontrolled cardiac arrhythmia, arterial thrombosis, cerebrovascular event,&#xD;
             pulmonary embolism).&#xD;
&#xD;
          -  Chronic active infection.&#xD;
&#xD;
          -  Any other concurrent severe or uncontrolled disease preventing the safe administration&#xD;
             of study drugs.&#xD;
&#xD;
          -  Any impairment of gastrointestinal function or -disease that may significantly impair&#xD;
             the absorption of oral drugs (i.e. uncontrolled nausea, vomiting, diarrhoea (defined&#xD;
             as CTC grade 2 or higher), malabsorption syndrome, bowel obstruction, or inability to&#xD;
             swallow tablets).&#xD;
&#xD;
          -  Concomitant treatments: concomitant (or within 4 weeks before start of the study)&#xD;
             administration of any other experimental drug under investigation; concurrent&#xD;
             treatment with any other anti-cancer therapy.&#xD;
&#xD;
          -  Continuous use of systemic immunosuppressive agents (except the use of corticosteroids&#xD;
             as anti-emetic prophylaxis/treatment).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H WM van Laarhoven, MD,PHD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Center, Medical Oncology</name>
      <address>
        <city>Amsterdam</city>
        <zip>1100 DD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 16, 2014</study_first_submitted>
  <study_first_submitted_qc>January 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2015</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>H.W.M. van Laarhoven</investigator_full_name>
    <investigator_title>Prof. Dr. H.W.M. van Laarhoven</investigator_title>
  </responsible_party>
  <keyword>Esophageal cancer</keyword>
  <keyword>Adjuvant treatment</keyword>
  <keyword>S-1</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Feasibility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

